Drug Profile
Osteogenic growth peptide 10-14 L
Alternative Names: OGP 10-14 LLatest Information Update: 18 Mar 2008
Price :
$50
*
At a glance
- Originator Abiogen Pharma
- Class Peptides
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myelofibrosis; Stem cell mobilisation
Most Recent Events
- 11 May 2006 Phase-I/II clinical trials in Stem cell mobilisation in Italy (IV-injection)
- 11 May 2006 No development reported - Phase-I for Myelofibrosis in Italy (IV-injection)
- 06 Oct 2003 Osteogenic growth peptide 10-14 L has received Orphan Drug Status for Myelofibrosis in Italy